I'm LongbridgeAI, I can summarize articles.Jibeier Pharmaceutical recently received the "Drug Registration Certificate" for Diclofenac Acid Tablets issued by the National Medical Products Administration. This medication is used to treat pain and inflammation caused by osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and has significant anti-inflammatory, analgesic, and antipyretic effects. The approved dosage form is tablets, while the previously marketed form was enteric-coated tablets
According to the Zhitong Finance APP, Jibeier Pharmaceutical (688566.SH) announced that it has recently received the "Drug Registration Certificate" for Diclofenac Sodium Tablets issued by the National Medical Products Administration.
The indications for this drug are for the treatment of symptoms related to pain and inflammation caused by osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Diclofenac Sodium is a non-steroidal anti-inflammatory drug with a wide range of clinical applications in the treatment and relief of pain, demonstrating significant anti-inflammatory, analgesic, and antipyretic effects. The dosage form previously marketed by the company was enteric-coated tablets, and the dosage form approved this time is tablets